Results 141 to 150 of about 6,775 (167)
Some of the next articles are maybe not open access.
Obinutuzumab for the First-Line Treatment of Follicular Lymphoma [PDF]
New England Journal of Medicine, 2017 Rituximab-based immunochemotherapy has improved outcomes in patients with follicular lymphoma. Obinutuzumab is a glycoengineered type II anti-CD20 monoclonal antibody.
Wolfram Klapper +2 more
exaly +4 more sources
Obinutuzumab Induces Depletion of NK Cells in Patients with Chronic Lymphocytic Leukemia [PDF]
Immunotherapy, 2018 Aim: Obinutuzumab induces NK cell antibody-dependent cell-mediated cytotoxicity. Objective: Investigate the effects on the human immune system after obinutuzumab monotherapy treatment in patients with chronic lymphocytic leukemia (CLL).
Elena Dominguez +2 more
exaly +2 more sources